Wegovy weight loss reviews: what the clinical evidence and real-world data tell us

The STEP 1 numbers that lie behind every Wegovy review you've read

When people post Wegovy reviews for weight loss online, the backdrop is a well-powered clinical trial. STEP 1 randomised 1,961 adults with obesity or overweight plus at least one weight-related condition to either semaglutide 2.4 mg or a placebo, with both groups following the same reduced-calorie diet and activity guidance. After 68 weeks the semaglutide group had lost an average of 14.9% of body weight; the placebo group lost 2.4%. About 70% of semaglutide participants hit the 5%-or-more threshold that clinicians use as a meaningful benchmark, and roughly a third lost more than 20%.

Those are averages. Individual results in reviews on Wegovy weight loss vary considerably, and trial conditions (structured support, regular check-ins, consistent supply) don't always match everyday life. The NICE appraisal of semaglutide (TA875) weighed this evidence and recommended the treatment within specialist weight management services, noting that the 15% average loss is clinically meaningful for people managing obesity-related conditions such as high blood pressure or type 2 diabetes. That clinical context is worth holding alongside any individual account you come across.

One thing the reviews rarely mention: most participants in STEP 1 regained a substantial portion of lost weight within a year of stopping treatment. The medicine works while you take it; the long-term picture depends on whether lifestyle changes stick and whether treatment continues. That is not a reason to dismiss the results, it is simply what the data show.

The 7.2 mg dose: what updated evidence adds to the picture

Wegovy reviews from people who started treatment before 2026 will mostly describe the 2.4 mg maintenance dose. The picture shifted in April 2026 when the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, a single weekly injection using an auto-dosing mechanism with a covered, locked needle. Trial data at that dose reported average weight loss of around 20.7% over 72 weeks, which begins to approach the results seen with tirzepatide (Mounjaro) at its highest dose. For readers who've been comparing Wegovy and Mounjaro based on older data, the 7.2 mg approval makes the comparison more nuanced than many review articles suggest.

The titration schedule stays the same regardless of eventual dose: treatment begins at 0.25 mg and steps up approximately every four weeks under prescriber guidance, with 7.2 mg as the new ceiling. That gradual escalation is the main reason the GI side effects in reviews tend to be worst early on and then settle. Pausing a titration step (common if nausea is significant around the time of a dose increase) is a clinical decision, not something to do based on a forum post. If you're curious about how people describe Wegovy's side effects specifically, those accounts map closely onto what the clinical data predict.

Availability of specific dose formats is confirmed at consultation rather than assumed; the prescriber and pharmacy work from current stock and clinical need.

What wegovy weight loss reviews in the UK miss, and what to weigh instead

UK reviews of Wegovy for weight loss are increasingly common, but a few patterns recur that are worth reading critically. First, many reviews don't distinguish between NHS and private routes. On the NHS, Wegovy is available through specialist services under TA875's criteria, BMI of 35 or above with at least one comorbidity, for a maximum of two years. Private access through a regulated online pharmacy like ours opens an alternative path without a referral or waiting list, subject to clinical assessment. The experience (and the cost) differs between those routes, and reviews about Wegovy often don't say which route the writer used.

Second, many reviews don't account for what was happening alongside the medicine. Semaglutide works partly by slowing gastric emptying and reducing appetite; people who also changed what they ate and moved more consistently tend to report better results, and those considering combination approaches may find it useful to read semaglutide with B12 for weight loss reviews to understand how that variant compares in practice. The NHS semaglutide medicines page is a good starting point for understanding what the medicine does and doesn't do on its own.

Third, cost shapes experience. Reviews from people who had supply disrupted mid-treatment, or who stopped because of expense, read very differently from those with consistent access. If you're weighing up the financial side, a straightforward look at what Wegovy costs in the UK and what a transparent private prescription includes is more useful than comparing fragments from review threads. And if you're the sort of person who plans big purchases around payday or likes to batch errands before a holiday, it's worth knowing that orders placed before noon on a working day (whenever that falls) are reviewed the same day and dispatched for next-working-day delivery if approved.

Reviews are one data point. The trial data, the regulator's guidance and a prescriber's assessment of your specific situation together give you a more complete answer than any single account. Our clinical team reviews every consultation personally. For a broader look at the options, the weight loss treatment overview covers how Wegovy sits alongside other licensed medicines.